Moreover, a clinical trial with the IgG4‐based CD47 antibody CC‐90002 in relapsed/refractory AML or high‐risk MDS (23/28) was discontinued after 82% of patients developed febrile neutropenia and four patients developed grade 4 toxicity.14 Here, CD47 is linked to myelodysplastic syndrome.